Phase 2 N=65 AllogeneiC Human Mesenchymal Stem Cells (hMSC) in Patients With Aging FRAilTy Via IntravenoUS Delivery
Frailty
Primary: Incidence of Any Treatment Emergent - Serious Adverse Events (TE-SAEs) — 0; 0; 0; 0 Incidents
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=67 Phase 2 Efficacy, Safety, and Tolerability Study of Natalizumab in Focal Epilepsy
Epilepsy, Focal Seizures, Partial Seizures
Primary: Change From Baseline in Log-Transformed Seizure Frequency During Weeks 8 to 24 of Treatment — -0.43; -0.58 log(seizure/28 days) — p=0.5053
Phase 2 N=53 Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma
Sarcoma, Alveolar Soft Part
Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants
Phase 2 N=24 Study to Evaluate Effects of Emixustat Hydrochloride in Subjects With Proliferative Diabetic Retinopathy
Proliferative Diabetic Retinopathy
Primary: Change in Aqueous Humor Concentration of the Following Biomarkers:IL-6, IL-8, IP-10, PDGF-AA, TGFβ-1, MCP-1, IL-1β, and VEGF, to be Reported in pg/mL Values — 45.6; 4.9…
Phase 2 N=64 High Dose Intravenous Thiamine for the Prevention of Delirium in Allogeneic Hematopoietic Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation · Delirium · Thiamine Deficiency
Primary: Percentage of Participants With Delirium — 25; 21 percentage of participants
Phase 2 N=200 Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children
Healthy Volunteers
Primary: Percentage of Participants With Cellular Immune Response to 2 Doses of Tetravalent Dengue Vaccine (TDV) at 1 Month Post Second Vaccination — 97.1 percentage of…
Phase 2 N=160 A Study to Evaluate Patient Preference and Satisfaction of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Participants With HER2-Positive Early Breast Cancer
HER2-Positive Early Breast Cancer
Primary: Percentage of Participants by Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 1 of the Patient Preference Questionnaire…
Phase 2 N=125 Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure
Ischemic Cardiomyopathy
Primary: Change From Baseline in Left Ventricular Ejection Fraction (LVEF) — -0.42; 0.37; 1.05; -0.33 percentage of end diastolic volume — p=0.993
Phase 2 N=17 Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors
Advanced Solid Tumors · Metastatic Solid Tumors
Primary: Maximum Tolerated Dose (MTD) — 10.0 mg/kg KW-0761IV
Phase 2 N=555 Effectiveness of an Antimicrobial Agent for Preoperative Skin Preparation
Preoperative Skin Preparation
Primary: Antimicrobial Activity of the Investigational Products Compared to Control. — 3.85; 3.91; 3.87; 3.84 log10 CFU/cm^2
Phase 2 N=53 Oral LAT8881 in Neuropathic Pain
Neuropathic Pain · Diabetic Peripheral Neuropathy (DPN) · Post Herpetic Neuralgia (PHN)
Primary: Absolute Change in Mean Pain Score, Using an 11 Point Numeric Pain Rating Scale (NPRS) — -0.87; -0.74 score on a scale — p=0.67
Phase 2 N=72 Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients
Metastatic Castrate-resistant Prostate Cancer · Adenocarcinoma, Prostate
Primary: Number of Patients Who Experience Dose Limiting Toxicities by Dose Level — 0; 0; 0; 0 Participants
Phase 2 N=99 Evaluation of the Antimicrobial Effectiveness of an Antimicrobial Cloth
Preoperative Skin Preparation
Primary: Bacterial Count at 10 Minutes Post Application — 3.55; 3.61; 3.66; 1.19 log10 CFU/cm^2
Phase 2 N=221 The Safety and Efficacy of Lucinactant for Inhalation in Premature Neonates 26 to 32 Weeks Gestational Age
Respiratory Distress Syndrome
Primary: Number of Participants With Respiratory Failure or Death Due to Respiratory Distress Syndrome (RDS) — 31; 32; 31 Participants — p=0.363
Phase 2 N=34 Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701
Enterotoxigenic Escherichia Coli Infection · Diarrhea
Primary: Percentage of Subjects With Moderate to Severe Diarrhea — 7; 11 Participants